```html

Episcleritis – A Complete Medical Guide

Overview

Episcleritis is an inflammation of the thin, highly vascular layer of tissue that lies between the conjunctiva (the clear membrane covering the white part of the eye) and the sclera (the white outer coat of the eye). The condition is usually benign, self‑limiting, and does not affect vision in most cases.

• Who it affects: Adults between 20–50 years are most commonly diagnosed, but children and older adults can develop it as well.
• Gender: Slight female predominance (≈55 % of cases) has been reported.
• Prevalence: Episcleritis accounts for roughly 5–10 % of all ocular inflammatory disorders seen in primary‑care ophthalmology clinics. Exact population‑based rates are low, estimated at 1–2 cases per 1,000 person‑years.<sup>1</sup>

Symptoms

The clinical picture is usually mild, but a thorough symptom list helps differentiate episcleritis from more serious eye conditions.

• Redness of the eye – a localized “bloodshot” appearance usually confined to one quadrant.
• Burning or gritty sensation – described as the feeling of a foreign body.
• Mild pain or ache – often less severe than in scleritis; pain improves with eye movement.
• Tearing – watery discharge, sometimes mistaken for allergic conjunctivitis.
• Photophobia – mild sensitivity to bright light, not usually disabling.
• Swelling of the episcleral vessels – visible as a localized “spot” of redness that can be moved with a cotton tip applicator (the “blanching” test).
• No impact on visual acuity – vision remains normal in >95 % of cases.

Causes and Risk Factors

In most patients, the exact trigger is unknown (idiopathic). However, several underlying mechanisms have been identified.

Immune‑mediated inflammation

• Autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus, or inflammatory bowel disease can precipitate episcleritis in 10–20 % of patients.<sup>2</sup>

Infectious triggers

• Rarely, bacterial or viral infections (e.g., herpes simplex, adenovirus) can involve the episcleral tissue.

Environmental and lifestyle factors

• Exposure to wind, dust, smoke, or chlorine (swimming pools) may irritate the episcleral vessels.
• Contact lens wear – especially if lenses are not cleaned properly.
• Trauma or prior ocular surgery.

Risk groups

• People with known systemic inflammatory disorders.
• Individuals who frequently work outdoors or in dusty environments.
• Patients on immunomodulatory therapy (e.g., biologics) – paradoxically, the medication can both trigger and suppress episcleritis.

Diagnosis

Diagnosis is primarily clinical, based on history and slit‑lamp examination. The goal is to confirm episcleritis and exclude more dangerous conditions such as scleritis, keratitis, or acute angle‑closure glaucoma.

Key steps

1. History taking – onset, laterality, associated systemic disease, medication use, and exposure to irritants.
2. Visual acuity test – should be normal.
3. Slit‑lamp examination – reveals a focal, superficial injection of blood vessels that typically blanches with phenylephrine 2.5 % drops, confirming episcleral involvement.
4. Fluorescein staining – usually negative (no corneal defects).
5. Phenylephrine test – differentiates episcleritis (blanches) from scleritis (does not blanch).

When ancillary tests are ordered

• Blood work (CBC, ESR, CRP, ANA, rheumatoid factor) if an autoimmune disease is suspected.
• Serologic testing for infections (HSV, VZV) in atypical presentations.
• Ultrasound biomicroscopy or anterior segment OCT in ambiguous cases.

Treatment Options

Because most episodes are self‑limited, treatment focuses on symptom relief and addressing any underlying systemic disease.

1. Observation

For mild, painless cases, watchful waiting is acceptable. Symptoms often resolve within 1–3 weeks without intervention.

2. Topical therapies

• Artificial tears – lubricate the eye and reduce the gritty sensation.
• Topical NSAIDs (e.g., ketorolac 0.5 % drops) – provide faster reduction of redness and discomfort.
• Topical corticosteroids (e.g., prednisolone acetate 1 %) – reserved for severe or persistent cases; used for 1–2 weeks with close monitoring for intra‑ocular pressure rise.

3. Oral medications

• Oral NSAIDs (ibuprofen 400 mg TID) – helpful when bilateral or when topical therapy is insufficient.
• Systemic corticosteroids – rarely needed, only when episcleritis is part of a systemic flare.

4. Management of underlying disease

If an autoimmune condition is identified, coordination with a rheumatologist or internist is essential. Disease‑modifying anti‑rheumatic drugs (DMARDs) or biologics can reduce recurrence.

5. Procedural options (rare)

In chronic, refractory cases, low‑dose subconjunctival injection of triamcinolone may be considered, but evidence is limited.

Living with Episcleritis

Most patients resume normal activities quickly, but a few practical steps can make the experience more comfortable.

• Protect the eyes – wear sunglasses outdoors to reduce wind‑driven irritation.
• Practice good hygiene – wash hands before touching the eyes; avoid rubbing.
• Limit contact lens wear – give the eyes a break, especially during flare‑ups.
• Use preservative‑free artificial tears several times daily.
• Track recurrences – keep a simple diary noting triggers, duration, and treatment response.
• Stay hydrated and manage stress – systemic inflammation can be modulated by lifestyle.

Prevention

Because many episodes are idiopathic, absolute prevention is impossible, yet risk can be lowered.

• Control systemic inflammatory diseases with appropriate medication and regular follow‑up.
• Avoid known ocular irritants: dusty environments, cigarette smoke, chlorinated water.
• Maintain proper contact‑lens hygiene or consider glasses during high‑risk periods.
• Use protective eyewear when performing yard work or using power tools.
• Adopt a balanced diet rich in omega‑3 fatty acids, which may have mild anti‑inflammatory effects.

Complications

Complications are uncommon, but failure to recognize a more serious condition can lead to:

• Scleritis – a deeper, painful inflammation that can threaten vision if untreated.
• Secondary infection – especially if corticosteroids are used without proper monitoring.
• Elevated intra‑ocular pressure (IOP) from topical steroid overuse, potentially causing glaucoma.
• Recurrence – up to 30 % of patients experience repeat episodes, often linked to an underlying systemic disease.

When to Seek Emergency Care

References

1. Mayo Clinic. “Episcleritis.” Accessed May 2024. https://www.mayoclinic.org
2. American Academy of Ophthalmology. “Episcleritis.” 2023. https://www.aao.org
3. National Eye Institute (NEI). “Scleritis and Episcleritis.” 2022. https://nei.nih.gov
4. Cleveland Clinic. “Eye Redness – What It Means.” 2023. https://my.clevelandclinic.org
5. World Health Organization. “Global estimates of visual impairment.” 2021. https://www.who.int

```